Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in p53-Mutant and p53 Wild-Type Malignancies
NCT03560882Phase 1Active, not recruiting
- Start
- Jul 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atorvastatin in solid tumor and acute myeloid leukemia (AML). Primary endpoint: Change in conformational mutant tumor protein 53 (p53) at 4 weeks. Started Jul 2018; status: active, not recruiting.
02
Drugs
atorvastatin
03
Conditions
solid tumoracute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03560882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560882.